Search results
Jun 3, 2021 · Michael Rosenblum received an experimental new prostate cancer treatment after the disease spread to his bones. Since then, he has been symptom-free. Update: On March 23, 2022, the US Food and Drug Administration approved 177 Lu-PSMA-617 for prostate cancer that has spread and grown resistant to other drugs.
- FDA Approves Promising Therapy for Advanced Prostate Cancer: Targets a ...
In 2019, Michael Rosenblum received an experimental new...
- A Major Advance: Tracking and Treating Hidden Prostate Cancer Cells
Michael Rosenblum received an experimental new prostate...
- FDA Approves Promising Therapy for Advanced Prostate Cancer: Targets a ...
Mar 23, 2022 · In 2019, Michael Rosenblum received an experimental new prostate cancer treatment after the disease spread to his bones. Since then, he has been symptom-free. The treatment is now FDA-approved.
Jun 3, 2021 · Prostate cancer treatment: A new drug, LU-PSMA-617, targets a protein, prostate-specific membrane antigen (PSMA) that is found on most prostate cancer cells.
Jul 1, 2021 · Michael Rosenblum received an experimental new prostate cancer treatment after the disease spread to his bones. Since then, he has been symptom-free. A transformation is coming for patients with prostate cancer, says Memorial Sloan Kettering medical oncologist Michael Morris.
Jul 12, 2023 · In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
Jan 9, 2024 · Summary: More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of...
Jun 4, 2021 · Doctors are reporting improved survival in men with advanced prostate cancer from an experimental drug that delivers radiation directly to tumor cells. Few such drugs are approved now, but the approach may become a new way to treat patients with other hard-to-reach or inoperable cancers.
